Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters








Database
Language
Publication year range
1.
Sci Rep ; 10(1): 6201, 2020 04 10.
Article in English | MEDLINE | ID: mdl-32277089

ABSTRACT

Broadly neutralising antibodies (bNAbs) against human immunodeficiency virus type 1 (HIV-1), such as CAP256-VRC26 are being developed for HIV prevention and treatment. These Abs carry a unique but crucial post-translational modification (PTM), namely O-sulfated tyrosine in the heavy chain complementarity determining region (CDR) H3 loop. Several studies have demonstrated that plants are suitable hosts for the generation of highly active anti-HIV-1 antibodies with the potential to engineer PTMs. Here we report the expression and characterisation of CAP256-VRC26 bNAbs with posttranslational modifications (PTM). Two variants, CAP256-VRC26 (08 and 09) were expressed in glycoengineered Nicotiana benthamiana plants. By in planta co-expression of tyrosyl protein sulfotransferase 1, we installed O-sulfated tyrosine in CDR H3 of both bNAbs. These exhibited similar structural folding to the mammalian cell produced bNAbs, but non-sulfated versions showed loss of neutralisation breadth and potency. In contrast, tyrosine sulfated versions displayed equivalent neutralising activity to mammalian produced antibodies retaining exceptional potency against some subtype C viruses. Together, the data demonstrate the enormous potential of plant-based systems for multiple posttranslational engineering and production of fully active bNAbs for application in passive immunisation or as an alternative for current HIV/AIDS antiretroviral therapy regimens.


Subject(s)
Antibodies, Neutralizing/genetics , HIV Antibodies/genetics , Nicotiana/genetics , Plants, Genetically Modified/genetics , Antibodies, Neutralizing/immunology , Biotechnology , Genetic Engineering , HIV Antibodies/immunology , HIV Infections/immunology , HIV Infections/therapy , HIV-1/genetics , HIV-1/immunology , Humans , Plants, Genetically Modified/immunology , Protein Engineering , Protein Processing, Post-Translational , Nicotiana/immunology
2.
PLoS One ; 11(7): e0159313, 2016.
Article in English | MEDLINE | ID: mdl-27427976

ABSTRACT

Rabies is a neglected zoonotic disease that has no effective treatment after onset of illness. However the disease can be prevented effectively by prompt administration of post exposure prophylaxis which includes administration of passive immunizing antibodies (Rabies Immune Globulin, RIG). Currently, human RIG suffers from many restrictions including limited availability, batch-to batch inconsistencies and potential for contamination with blood-borne pathogens. Anti-rabies monoclonal antibodies (mAbs) have been identified as a promising alternative to RIG. Here, we applied a plant-based transient expression system to achieve rapid, high level production and efficacy of the two highly potent anti-rabies mAbs E559 and 62-71-3. Expression levels of up to 490 mg/kg of recombinant mAbs were obtained in Nicotiana benthamiana glycosylation mutants by using a viral based transient expression system. The plant-made E559 and 62-71-3, carrying human-type fucose-free N-glycans, assembled properly and were structurally sound as determined by mass spectrometry and calorimetric density measurements. Both mAbs efficiently neutralised diverse rabies virus variants in vitro. Importantly, E559 and 62-71-3 exhibited enhanced protection against rabies virus compared to human RIG in a hamster model post-exposure challenge trial. Collectively, our results provide the basis for the development of a multi-mAb based alternative to RIG.


Subject(s)
Antibodies, Monoclonal/biosynthesis , Antibodies, Viral/biosynthesis , Immunization, Passive , Nicotiana/genetics , Rabies/prevention & control , Agrobacterium tumefaciens/genetics , Agrobacterium tumefaciens/metabolism , Animals , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/genetics , Antibodies, Viral/administration & dosage , Antibodies, Viral/genetics , Cloning, Molecular , Female , Gene Expression , Genetic Vectors/chemistry , Genetic Vectors/metabolism , Mesocricetus , Neutralization Tests , Plants, Genetically Modified , Rabies/immunology , Rabies/mortality , Rabies/virology , Rabies Vaccines/administration & dosage , Rabies Vaccines/biosynthesis , Rabies virus/drug effects , Rabies virus/growth & development , Rabies virus/immunology , Rabies virus/pathogenicity , Recombinant Proteins/administration & dosage , Recombinant Proteins/biosynthesis , Recombinant Proteins/genetics , Survival Analysis , Nicotiana/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL